ArticleOsteoporosis and sarcopenia2026
Fall risk in rheumatoid arthritis revisited: A follow-up study focusing on sarcopenia and glucocorticoid use.
Article in Osteoporosis and sarcopenia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To re-evaluate fall incidence and its determinants in a contemporary cohort of ambulatory women with rheumatoid arthritis (RA) in a follow-up study based on our previously published cohort data. Methods: We prospectively evaluated 124 ambulatory female patients aged ≥50 years with RA at a single institution in 2022-2023, monitoring falls for 1 year. Outcomes included patient characteristics, sarcopenia, disease activity, and physical function. Multivariable logistic regression and Firth-penalized logistic regression were used in sensitivity analysis to assess the interaction between sarcopenia and glucocorticoid (GC) use. Results: The annual fall rate in the 2022-2023 cohort was lower than in our previous cohort (27.4% vs. 50.0%). History of falls (odds ratio [OR] 2.76, 95% confidence interval [CI] 1.02-7.45, P = 0.045) and hypnotics/anxiolytics use (OR 3.92, 95% CI 1.01-15.20, P = 0.048) were independent risk factors for falls. A significant interaction between sarcopenia and GC use was observed in the initial analysis but was no longer statistically significant in sensitivity analyses. Conclusions: Compared with our previously reported cohort, the contemporary RA cohort showed a lower fall rate and a different pattern of associated risk factors. Further research is needed to explore the potential interaction between sarcopenia and glucocorticoid use. The observed interaction should be considered exploratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.